Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689219 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Nabil Adra.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02689219 is a Phase 2 study that was terminated before completion, run by Nabil Adra. The registered enrollment target is 18 participants.
The verdict
NCT02689219, a Phase 2 study, was terminated before completion, sponsored by Nabil Adra.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
Interventions
- DRUG Brentuximab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02689219
The ClinicalTrials.gov registry entry for NCT02689219 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabil Adra, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brentuximab Vedotin is the first listed.
NCT02689219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02689219 about?
NCT02689219 is a clinical study titled "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors". This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
What is the current status of trial NCT02689219?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-03-09. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT02689219?
The interventions under investigation include: Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02689219?
This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.